摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[1-(1-Phenylcycloheptyl)piperidin-4-yl]-3-(2-piperidin-1-ylethyl)benzimidazol-2-one

中文名称
——
中文别名
——
英文名称
1-[1-(1-Phenylcycloheptyl)piperidin-4-yl]-3-(2-piperidin-1-ylethyl)benzimidazol-2-one
英文别名
——
1-[1-(1-Phenylcycloheptyl)piperidin-4-yl]-3-(2-piperidin-1-ylethyl)benzimidazol-2-one化学式
CAS
——
化学式
C32H44N4O
mdl
——
分子量
500.7
InChiKey
OORFFCUVUXBZJX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6
  • 重原子数:
    37
  • 可旋转键数:
    6
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    30
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • [EN] NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH<br/>[FR] AGONISTES DU RECEPTEUR ORL-1 DE LA NOCICEPTINE UTILISES POUR LE TRAITEMENT DE LA TOUX
    申请人:SCHERING CORP
    公开号:WO2001007050A1
    公开(公告)日:2001-02-01
    The present invention relates to the use of ORL-1 receptor agonists for the treatment of cough, alone or in combination with one or more agents for the treatment of cough, allergy or asthma symptoms, in particular to the use of ORL-1 agonists of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: the dotted line represents and optional double bond; X1 is optionally substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl; X2 is-CHO, -CN, optionally substituted amino, alkyl, or aryl; or X1 is optionally substituted benzofused heterocyclyl and X2 is hydrogen; or X?1 and X2¿ together form an optionally benzofused spiro heterocyclyl group R?1, R2, R3 and R4¿ are independently H and alkyl, or (R?1 and R4) or (R2 and R3) or (R1 and R3) or (R2 and R4¿) together can form an alkylene bridge of 1 to 3 carbon atoms; Z1 is optionally substituted alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, or -CO¿2?(alkyl or substituted amino) or CN; Z?2¿ is H or Z1; Z3 is H or alkyl; or Z?1, Z2 and Z3¿, together with the carbon to which they are attached, form bicyclic saturated or unsaturated rings.
    本发明涉及使用ORL-1受体激动剂治疗咳嗽,单独或与一种或多种用于治疗咳嗽、过敏或哮喘症状的药物组合使用,特别是使用式(I)的ORL-1激动剂或其药学上可接受的盐或溶剂,其中:虚线代表可选的双键;X1是可选的取代基的烷基、环烷基、芳基、杂芳基或杂环烷基;X2是-CHO、-CN、可选的取代氨基、烷基或芳基;或X1是可选的取代苯并杂环基,X2是氢;或X1和X2一起形成可选的苯并螺杂环基团;R1、R2、R3和R4独立地为H和烷基,或(R1和R4)或(R2和R3)或(R1和R3)或(R2和R4)一起形成1至3个碳原子的烷基桥;Z1是可选的取代基的烷基、芳基、杂芳基、环烷基或杂环烷基,或-CO2(烷基或取代氨基)或-CN;Z2是H或Z1;Z3是H或烷基;或Z1、Z2和Z3,与它们连接的碳一起,形成二环饱和或不饱和环。
  • 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS
    申请人:PFIZER INC.
    公开号:EP1049689A1
    公开(公告)日:2000-11-08
  • NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH
    申请人:SCHERING CORPORATION
    公开号:EP1200087A1
    公开(公告)日:2002-05-02
  • High affinity ligands for nociceptin receptor ORL-1
    申请人:Schering-Plough Corporation
    公开号:US20040067950A1
    公开(公告)日:2004-04-08
    The present invention relates to the method of treating cough with ORL-1 agonists, alone or in combination with additional agents for treating symptoms of cough, allergy or asthma, pharmaceutical compositions comprising the combinations, and to compounds of the formula 1 or a pharmaceutically acceptable salt or solvate thereof, wherein: the dotted line represents an optional double bond; X 1 is optionally substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl; X 2 is —CHO, —CN, optionally substituted amino, alkyl, or aryl; or X 1 is optionally substituted benzofused heterocyclyl and X 2 is hydrogen; or X 1 and X 2 together form an optionally benzofused spiro heterocyclyl group R 1 , R 2 , R 3 and R 4 are independently H and alkyl, or (R 1 and R 4 ) or (R 2 and R 3 ) or (R 1 and R 3 ) or (R 2 and R 4 ) together can form an alkylene bridge of 1 to 3 carbon atoms; Z 1 is optionally substituted alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, or —CO 2 (alkyl or substituted amino) or CN ; Z 2 is H or Z 1 ; Z 3 is H or alkyl; or Z 1 , Z 2 and Z 3 , together with the carbon to which they are attached, form bicyclic saturated or unsaturated rings; pharmaceutical compositions therefore, and the use of said compounds as nociceptin receptor inhibitors useful in the treatment of pain, anxiety, cough, asthma, depression and alcohol abuse.
  • US6423725B1
    申请人:——
    公开号:US6423725B1
    公开(公告)日:2002-07-23
查看更多